Biblio

Author Title [ Type

] Year

Filters: Author is Duell, Johannes [Clear All Filters]

Journal Article

Fischer L, Jiang L, Bittenbring JThomas, Huebel K, Schmidt C, Duell J, Metzner B, Krauter J, Glass B, Huettmann A, et al. The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis. Ann Hematol. 2023.

Werner R, Haug A, Buske C, Heidegger S, Illert AL, Bassermann F, Herhaus P, Buck A, Duell J, Topp MS, et al. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Nuklearmedizin. 2024.

Gagelmann N, Wulf GGeorg, Duell J, Glass B, van Heteren P, von Tresckow B, Fischer M, Penack O, Ayuk FA, Einsele H, et al. Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study. Blood Adv. 2022.

Pemmaraju N, Deconinck E, Mehta P, Walker I, Herling M, Garnache-Ottou F, Gabarin N, Campbell CJV, Duell J, Moshe Y, et al. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Lymphoma Myeloma Leuk. 2023.

Belada D, Kopeckova K, Burgues JMiguel Ber, Stevens D, André M, Persona EPerez, Pichler P, Staber PB, Trneny M, Duell J, et al. Safety and efficacy of tafasitamab ± lenalidomide added to first-line R‑CHOP for DLBCL: Phase 1b First-MIND study. Blood. 2023.

Duell J, Abrisqueta P, André M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AMarina, Maddocks KJ, Menne T, et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study. Haematologica. 2023.

Salles G, Duell J, Barca EGonzález, Tournilhac O, Jurczak W, Liberati AMarina, Nagy Z, Obr A, Gaidano G, André M, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020.